Vitrafy Life Sciences Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Net Income	-16.17	-32.71	-10.43	-7.81	-7.66
Depreciation & Amortization	0.12	0.15	0.21	0.26	0.19
Other Amortization	-	-	2.03	0.81	-
Asset Writedown & Restructuring Costs	0.17	-	-	-	-
Stock-Based Compensation	0.53	2.08	0.19	0.36	0.11
Other Operating Activities	0	18.9	1.78	0.65	3.03
Change in Accounts Receivable	-0.53	-0.45	-0.05	-0.02	-0.02
Change in Accounts Payable	0.59	0.37	-0.23	0.31	-0.11
Change in Unearned Revenue	-1.43	1.43	-	-	-
Change in Other Net Operating Assets	0.94	1.43	-0.3	0.49	-1.42
Operating Cash Flow	-15.77	-8.8	-6.79	-4.96	-5.87
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-0.54	-0	-0.01	-0.09	-0.49
Investment in Securities	-5	-10.08	-	-	-
Investing Cash Flow	-5.54	-10.08	-0.01	-0.09	-0.49
Short-Term Debt Issued	-	-	12.55	6.31	-
Total Debt Issued	-	-	12.55	6.31	-
Short-Term Debt Repaid	-	-	-0.55	-0.4	-
Long-Term Debt Repaid	-0.09	-0.08	-0.13	-0.1	-0.06
Total Debt Repaid	-0.09	-0.08	-0.68	-0.5	-0.06
Net Debt Issued (Repaid)	-0.09	-0.08	11.87	5.82	-0.06
Issuance of Common Stock	30	35.32	0.27	0.09	-
Other Financing Activities	-2.03	-3.25	-0.64	-0.1	-
Financing Cash Flow	27.88	31.99	11.5	5.8	-0.06
Foreign Exchange Rate Adjustments	0.01	-	-	-	-
Net Cash Flow	6.58	13.11	4.69	0.76	-6.42
Free Cash Flow	-16.31	-8.8	-6.8	-5.05	-6.36
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Margin	-445.83%	-483.68%	-325.03%	-245.44%	-348.32%
Free Cash Flow Per Share	-0.25	-0.20	-2.22	-1.71	-2.17
Levered Free Cash Flow	-16.42	-17.87	-9.08	0.73	-
Unlevered Free Cash Flow	-16.41	-13.81	-2.56	3.86	-
Change in Working Capital	-0.43	2.78	-0.58	0.78	-1.55